
ASCO 2025: Real-World Data Supports Rechallenging Trastuzumab Deruxtecan After ILD
Trastuzumab deruxtecan (T-DXd, Enhertu; AstraZeneca and Daiichi Sankyo) has become a pivotal therapy in the treatment of HER2-positive cancers, yet its use is associated with the risk of interstitial lung disease (ILD), a potentially serious and sometimes …